News

Trial study at St Thomas’s Pain Management Centre shows dramatic effectiveness to treat chronic intractable pain

PRETORIA, South Africa, 27 March, 2018 — Xavant Technology (Pty) Ltd today announced the launch of their Stimpod NMS460 in the U.K. The Stimpod NMS460, a non-invasive neuromodulation device, is focused on the symptomatic relief and management of neuropathic pain as well as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

The NMS460 is already impacting the industry as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments. The device’s therapeutic effect is based on cellular metabolic activity observed when a neuropathic nerve is subjected to electromagnetic effects caused by pulsed radio frequency (PRF). The resulting cellular metabolic activity has shown to change the characteristics of the nerve, often causing the nerve to recover back to its normal function with instant and dramatic relief of pain. The Stimpod NMS460 uses technology featuring a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves.

Nearly half of the adult population in the U.K. is living with chronic pain with almost nine percent experiencing neuropathic pain[1]. Neuropathic pain is experienced mainly by some of the four million diabetics in the country; 60 to 70 percent of all who have diabetes experience neuropathy. Traditional treatment for this pain is typically not only expensive and often with unwanted side effects, but it also doesn’t directly target the root cause of the pain.

St. Thomas’ Hospital Pain Management Centre conducted the initial study of the predecessor to the NMS460, the NMS 300, and found dramatic reduction in pain by a majority of the participating patients. Highlights of the study include over 50 percent of patients experiencing 100 percent pain relief with the vast majority of the other patients having at least 50 percent improvement. The full results of the clinical trial study, as well as case reports, can be found here https://www.stimpodnms460.com/downloads/#1501856701449-dcc23634-16fe. The NMS 460 will be exhibited in April at the Physio First Conference in Nottingham.

“Already with great success in the U.S. and beyond, we cannot wait to see the impact that it will have across the globe,” said Roche Janse van Rensburg, Chairman of Xavant Technology (Pty) Ltd. “Our technology has the potential to change the lives of millions in the U.K. and the tens of millions of people across Europe who experience severe, chronic pain.”

[1] Bazian. (2016, June 21). Almost half of all UK adults may be living with chronic pain (NHS Choices, Ed.). Retrieved March 21, 2018, from https://www.nhs.uk/news/medical-practice/almost-half-of-all-uk-adults-may-be-living-with-chronic-pain/

Media Contact:
Lourie Höll
Phone: +27 12 743 5959
Email: media@xavant.com

Xavant Technology exhibiting at World Confederation for Physical Therapy Congress

NOTTINGHAM, United Kingdom, 9 March 2018 – Xavant Technology (Pty) Ltd is attending the Physio First Conference in Nottingham, the United Kingdom, from 27 to 29 April 2018. The company, who is a leading developer of nerve stimulators for regional and general anesthesia, obtained clearance from the U.S Food and Drug Administration’s (FDA) in June 2017 to distribute their latest device, the Stimpod NMS460 in the United States. Their eyes are now set on the United Kingdom.

“We are excited to officially launch the Stimpod NMS460 to the UK market,” said Roche van Rensburg, Chairman of Xavant Technology (Pty) Ltd. “Our ground-breaking technology has the ability to help thousands of people in the U.K. as a valuable treatment asset for physiotherapists, neurologists, chiropractors, and medical pain practitioners.”

The Stimpod NMS460’s patented proprietary hybrid pulsed radio frequency (PRF) waveform lets practitioner facilitate the symptomatic relief and management of chronic intractable pain. It is also indicated as an adjunctive treatment in the management of post-surgical pain, post-traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

The Stimpod NMS460 has the potential to have a massive impact on the physiotherapy community as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments.

The device applies its patented PRF waveform to the affected area transcutaneously. This waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments, and several case studies have shown instant and dramatic relief of chronic intractable pain. The Stimpod NMS460 also incorporates the nerve-locating technology which features a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves.

About Xavant Technology (Pty) Ltd

Xavant Technology (Pty) Ltd is a leading supplier of nerve stimulators for regional and general anesthesia applications. The current Stimpod range has three models – the NMS410, NMS450 and NMS460. The Stimpod NMS460 is a neuromodulation device used for symptomatic relief of chronic intractable pain, implementing a unique patented Pulsed Radio Frequency waveform for the treatment of neuropathies. The Stimpod NMS410 model is a specialized nerve locating device, with its unique nerve mapping and locating cable, used primarily during Regional Anesthesia procedures. The Stimpod NMS450 adds the option to monitor neuromuscular blocking agents with its advanced three-dimensional accelerometer.

Xavant CEO, Corlius Birkill, delivers presentation at the Academy of Integrative Pain Management’s 28th Annual Meeting

San Diego, United States of America (22 October 2017) – Xavant Technology (Pty) Ltd proud to announce their sponsorship of the 28th Annual Meeting of the Academy of Integrative Pain Management (AIPM).

The AIPM is the only national professional organization dedicated to advancing the integrative pain care approaches that now define “best practice” in the National Pain Strategy published by NIH.

Corlius Birkill, CEO of Xavant Technology, delivered a presentation on the company’s ground-breaking device, the Stimpod NMS460, explaining the science behind the technology and how it offers new hope for chronic pain and other intractable neuropathies.

“The Stimpod NMS460 will greatly impact the industry as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments…”

“There are 289 million opioid prescriptions written in the US per year and 33 000 deaths due to overdose. With 33% of Americans suffering from chronic pain, it’s clear that a new approach should be considered…”

Xavant Technology exhibiting at World Confederation for Physical Therapy Congress

Cape Town, South Africa (1 July 2017) – Xavant Technology (Pty) Ltd is attending the World Confederation for Physical Therapy (WCPT) congress in Cape Town, South Africa from 2 to 4 July 2017. The company, who is a leading developer of nerve stimulators for regional and general anesthesia, announced in June that it had obtained the U.S Food and Drug Administration’s (FDA) clearance to distribute their latest device, the Stimpod NMS460 in the United States.

“We are thrilled at the news that our revolutionary device can now be used in the U.S.,” said Corlius Birkill, CEO of Xavant Technology (Pty) Ltd. “This ground-breaking technology has the ability to help tens if not hundreds of millions of people just in the U.S. as a valuable treatment asset for neurologists, chiropractors, acupuncturists, physical therapists, physiatrists, and medical pain practitioners.”

With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive treatment in the management of post-surgical pain, post traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

The Stimpod NMS460 has the potential to have a massive impact on the physical therapy community as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments.

The device applies its patented PRF waveform to the affected area transcutaneously. This waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments, and several case studies have shown instant and dramatic relief of chronic intractable pain. The Stimpod NMS460 also incorporates the nerve-locating technology which features a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves.

About Xavant Technology (Pty) Ltd

Xavant Technology (Pty) Ltd is a leading supplier of nerve stimulators for regional and general anesthesia applications. The current Stimpod range has three models – the NMS410, NMS450 and NMS460. The Stimpod NMS460 is a neuromodulation device used for symptomatic relief of chronic intractable pain, implementing a unique patented Pulsed Radio Frequency waveform for the treatment of neuropathies. The Stimpod NMS410 model is a specialized nerve locating device, with its unique nerve mapping and locating cable, used primarily during Regional Anesthesia procedures. The Stimpod NMS450 adds the option to monitor neuromuscular blocking agents with its advanced three-dimensional accelerometer.

FDA Clears Xavant Technology’s Stimpod NMS460

Non-invasive neuromodulation device for treatment of chronic intractable pain

Pretoria, South Africa (1 August 2017) – Xavant Technology (Pty) Ltd today announced that the U.S. Food and Drug Administration (FDA) cleared their Stimpod NMS460. With the U.S. patent awarded on proprietary hybrid pulsed radio frequency (PRF) waveform, this non-invasive neuromodulation device is focused on the symptomatic relief and management of chronic intractable pain, as well as an adjunctive treatment in the management of post-surgical pain, post traumatic acute pain problems, and an adjunct for pain control due to rehabilitation.

The need for this device is profound. More than 100 million Americans report that they have a problem with pain.[1]  Chronic pain is characterized by neuroplastic changes that cause sensitization of the nervous system. These changes result in anatomical and physiological changes that affect neurological function, which causes long-term potentiation and gene expression changes that then allow the pain to continue with or without further peripheral input, and a lower pain threshold; this dysfunction then also accounts for the epiphenomena associated with the disease, including emotional, memory, and motor changes, which then becomes the illness of chronic pain.[2]

Treatment of chronic pain in the United States is estimated to cost $600 billion annually.[3] The current standard of care for chronic pain includes drug cocktails such as Corticosteroids, Opiate pain relievers, injections, and beyond combined with treatments like physical therapy and counseling. Treatments can come with various short-term and long-term side effects.

The Stimpod NMS460, however, will greatly impact the industry as a non-invasive, non-drug solution with zero side effects and a fast onset of effect at a fraction of the cost of comparable treatments. The device applies its patented PRF waveform to the affected area transcutaneously. This waveform creates electromagnetic effects similar to invasive pulsed radio frequency treatments, and several case studies have shown instant and dramatic relief of chronic intractable pain. The Stimpod NMS460 also incorporates the nerve-locating technology which features a nerve mapping probe that enables practitioners to locate nerves and evaluate the treatment progress of damaged nerves. Bell Medical has been selected as the master distributor for both the U.S. and Canada.

“We are thrilled at the news that our revolutionary device can now be used in the U.S.,” said Corlius Birkill, CEO of Xavant Technology (Pty) Ltd. “This ground-breaking technology has the ability to help tens if not hundreds of millions of people just in the U.S. as a valuable treatment asset for neurologists, chiropractors, acupuncturists, physical therapists, physiatrists, and medical pain practitioners.”

[1] Gaskin, Darrell J., and Patrick Richard. “The Economic Costs of Pain in the United States.” The Journal of Pain: Official Journal of the American Pain Society (2012): 715-24. Web. 21 June 2017.

[2] American Academy Of Pain Medicine. Neuropathic Pain Recognized as a Disease. N.p.: American Medical Association, 27 Sept. 2016. PDF. https://assets.ama-assn.org/sub/meeting/documents/i16-resolution-912.pdf

[3] Gaskin, Darrell J., and Patrick Richard. “The Economic Costs of Pain in the United States.” The Journal of Pain: Official Journal of the American Pain Society (2012): 715-24. Web. 21 June 2017.

Download as PDF